The newest patent covers methods of cleaving a target DNS in a prokaryotic cell using Cas9 protein in single-molecule DNA targeting RNAs. This patent specifically covers methods in bacterial cells.
In the fifth consecutive week, the U.S. Patent and Trademark Office (USPTO) has awarded a CRISPR-Cas9 patent to the University of California which has increased the compositions and methods covered in the portfolio.
The portfolio includes 16 patents marking the largest CRISPR-Cas9 patent portfolio in the country and is expected to rise to 18 in a few weeks after other applications have been issued as patents.
This huge portfolio covers compositions for the CRISPR-Cas9 gene-editing technology which includes targeting and editing genes and modulating transcription in any setting including within plants and human cells.
Eldora L. Ellison, Ph.D., lead patent strategist on CRISPR-Cas9 matters for UC and a Director at Sterne, Kessler, Goldstein & Fox, said this continued issuance of CRISPR-Cas9 to the University of CA has added new compositions and methods to their portfolio which has become the largest-ranging in technology.
They are so pleased with by USPTO's ongoing recognition of the Doudna-Charpentier team's leadership.
The Doudna-Charpentier team invented the CRISPR-Cas9 DNA-targeting technology includes Jennifer Doudna and Martin Jinek at the University of CA, Berkeley, Emmanuelle Charpentier, and Krzysztof Chylinskij at the University of Vienna.
The other methods claimed in UC's other issued patents that are set to be issued were included in the CRISPR-Cas9 gene-editing technology that was disclosed first by the Doudna-Charpentier team in May prior to the patent application.
Other CRISPR-Cas9 patents in the team's portfolio include: 10,000,772; 10,113,167; 10,227,611; 10,266,850; 10,301,651; 10,308,961; 10,337,029; 10,351,878; 10,358,658; 10,358,659; 10,385,360; 10,400,253; 10,407,697; 10,415,061; and 10,421,980.
The above patents are not a part of the PTAB’s most recently declared interference between 14 UC patent applications and many previously issued Board Institute patents along with one application which jeopardizes all of the Broad's CRISPR patents involving eukaryotic cells.
International patent offices have recognized the pioneering innovations of the Doudna-Charpentier team along with 6 patents granted in the U.S., the European Patent Office, which represents 30 countries, and various patent offices in the UK, New Zealand, Japan, China, Australia, Mexico, as well as other countries have issued patents for use of CRISPR-Cas9 gene editing in all types of cells.
The University of CA has a standing commitment to create and apply its patented technologies for the improvement of mankind. Consistent with its open-licensing policies, they allow nonprofit institutions to use the technology for non-commercial educational research purposes.
The University of CA, in reference to CRISPR-Cas9, has encouraged widespread commercialization of the technology through its exclusive license with Caribou Biosciences, Inc of Berkeley.
Caribou has sub-licensed the patent family to various companies around the world including Intellia Therapeutics Inc, for human therapeutic applications. Also, Charpentier has licensed the technology to CRISPR Therapeutics AG and ERS Genomics Limited.